Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie IncfiledCriticalAbbvie Inc
Publication of AR117097A1publicationCriticalpatent/AR117097A1/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Composiciones de 4’-monofosfato de levodopa y 4’-monofosfato de carbidopa que tienen una relación peso en peso de aproximadamente 20:1 y métodos para tratar el mal de Parkinson y condiciones asociadas mediante la administración subcutánea de dichas composiciones.Compositions of levodopa 4'-monophosphate and carbidopa 4'-monophosphate having a weight-to-weight ratio of about 20: 1 and methods for treating Parkinson's disease and associated conditions by subcutaneous administration of such compositions.
ARP190103368A2018-11-152019-11-15
PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION
AR117097A1
(en)
oral health treatment system for the application of amorphous calcium phosphate, use of one or more basic amino acids, composition, and use of one or more amino acids in an oral health treatment system